Literature DB >> 32154634

When Pigs Fly: A Multidisciplinary Approach to Navigating a Critical Heparin Shortage.

Rachel P Rosovsky1, Megan E Barra2, Russel J Roberts2, Alison Parmar3, Jennifer Andonian4, Larren Suh2, Suzanne Algeri3, Paul D Biddinger4,5.   

Abstract

A recent outbreak of African swine fever (ASF) in China has claimed the lives of millions of pigs, and although this virus has no health impacts on humans, the disruption of the global pig population has far-reaching negative impacts on economic and pork-derived products, including the creation of the critical drug heparin. The active pharmaceutical ingredient in heparin is derived from pig intestines, and because of the ASF outbreak, the U.S. faces an imminent shortage of heparin. This drug shortage has the potential for profound implications, as heparin is used in a substantial and varied number of medical conditions. In response to notification of the heparin shortage crisis, our institution, Massachusetts General Hospital, activated its Hospital Incident Command System to streamline organization of major stakeholders and oversee operational and clinical activities required to mitigate the potential risks and optimize alternative effective strategies. This article describes the essential elements of our institution's emergency response plan, including detailed clinical algorithms developed by our experts for maximal heparin conservation and waste reduction by promoting safe and effective alternative strategies. Through this practice, we have also identified opportunities to change providers' prescribing and utilization behaviors for the better. As the ASF has not yet been contained and this crisis continues, the strategies and policies employed by our institution can provide a framework for other institutions to tackle this ongoing challenge and future drug shortage crises. IMPLICATIONS FOR PRACTICE: A detailed description of how one institution addressed the current heparin crisis, to support heparin conservation and waste reduction, is provided. The strategies used helped decrease heparin use by 80% in less than 2 months of establishing the task force. This accomplishment can be credited to the development of a task force and strategic plan in which experts and stakeholders were quickly identified, offered a part in the decision-making process, and frequently updated. Furthermore, the response system was dynamic, accessible, and one in which challenges were recognized and acted upon. The key to any crisis management is respect for one another and constant and open communication. Heparin is such a widespread drug that this shortage can potentially affect every patient population and provider. Understanding one's institutional needs and the effect of this crisis on those needs is one of the first steps when developing a strategic plan. Continually evaluating and adjusting that approach in response to the needs of the institution are critical to its success. Moreover, as it did for the authors' institution, a constant appraisal of the strategies can lead to opportunities for improvements in organization and practice that can be sustained well beyond the crisis. © AlphaMed Press 2020.

Entities:  

Keywords:  African swine fever; Anticoagulants; Anticoagulation; Drug shortage; Heparin; Shortage

Mesh:

Substances:

Year:  2020        PMID: 32154634      PMCID: PMC7160421          DOI: 10.1634/theoncologist.2019-0910

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  27 in total

1.  The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.

Authors:  C Michael Gibson; Rim Halaby; Serge Korjian; Yazan Daaboul; Douglas F Arbetter; Megan K Yee; Samuel Z Goldhaber; Russel Hull; Adrian F Hernandez; Shiao-Ping Lu; Olga Bandman; Janet M Leeds; Alex Gold; Robert A Harrington; Alexander T Cohen
Journal:  Am Heart J       Date:  2016-12-18       Impact factor: 4.749

2.  2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force.

Authors:  John U Doherty; Ty J Gluckman; William J Hucker; James L Januzzi; Thomas L Ortel; Sherry J Saxonhouse; Sarah A Spinler
Journal:  J Am Coll Cardiol       Date:  2017-01-09       Impact factor: 24.094

3.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Authors:  José A Nieto; Noelia Garrido Espada; Ricardo Guijarro Merino; Timoteo Cámara González
Journal:  Thromb Res       Date:  2012-03-15       Impact factor: 3.944

Review 5.  Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).

Authors:  Terese T Horlocker; Erik Vandermeuelen; Sandra L Kopp; Wiebke Gogarten; Lisa R Leffert; Honorio T Benzon
Journal:  Reg Anesth Pain Med       Date:  2018-04       Impact factor: 6.288

6.  Supply Shortages: A Silver Lining.

Authors:  Arjun Gupta; Norman Mang; Wenjing Wei; Jessica Ortwine; Kavita Bhavan; David H Johnson; Deepak Agrawal
Journal:  Am J Med       Date:  2018-02-15       Impact factor: 4.965

7.  Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.

Authors:  Robert D McBane; Waldemar E Wysokinski; Jennifer G Le-Rademacher; Tyler Zemla; Aneel Ashrani; Alfonso Tafur; Usha Perepu; Daniel Anderson; Krishna Gundabolu; Charles Kuzma; Juliana Perez Botero; Roberto A Leon Ferre; Stanislav Henkin; Charles J Lenz; Damon E Houghton; Prakash Vishnu; Charles L Loprinzi
Journal:  J Thromb Haemost       Date:  2019-11-28       Impact factor: 5.824

Review 8.  Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review.

Authors:  Benjamin S Salter; Menachem M Weiner; Muoi A Trinh; Joshua Heller; Adam S Evans; David H Adams; Gregory W Fischer
Journal:  J Am Coll Cardiol       Date:  2016-05-31       Impact factor: 24.094

Review 9.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

Authors:  K Martin; J Beyer-Westendorf; B L Davidson; M V Huisman; P M Sandset; S Moll
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

10.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

View more
  4 in total

1.  Drug Shortages: The View Across an Ocean.

Authors:  Andrew Shuman; Yoram Unguru
Journal:  Oncologist       Date:  2020-02-06

2.  Preparing for COVID-19-related Drug Shortages.

Authors:  Andrew G Shuman; Erin Fox; Yoram Unguru
Journal:  Ann Am Thorac Soc       Date:  2020-08

Review 3.  The Role of Electronic Medical Records in Reducing Unwarranted Clinical Variation in Acute Health Care: Systematic Review.

Authors:  Tobias Hodgson; Andrew Burton-Jones; Raelene Donovan; Clair Sullivan
Journal:  JMIR Med Inform       Date:  2021-11-17

4.  Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery.

Authors:  Florian Wilhelmy; Annika Hantsche; Michael Gaier; Johannes Kasper; Michael Karl Fehrenbach; Rene Oesemann; Jürgen Meixensberger; Dirk Lindner
Journal:  Neurol Int       Date:  2021-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.